Improving the Use of FDA Advisory Committees

The authors examine the FDA’s use of advisory committees in regulatory decision-making, highlighting concerns about instances where the FDA has disregarded advisory committee recommendations—most notably in the approval of aducanumab for Alzheimer’s disease despite unanimous committee opposition. The authors propose reforms to strengthen the role and independence of these expert panels.